Elicio Therapeutics (Nasdaq: ELTX) announced that CEO Robert Connelly and CSO Pete DeMuth will present at the TD Cowen 46th Annual Health Care Conference in Boston, March 2-4, 2026. The company presentation is scheduled for March 4, 2026 at 1:10 PM ET.
According to Elicio, a live webcast and a 90-day replay will be available on the company Events page for investors who cannot attend in person.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – ELTX
+10.35%
12 alerts
+10.35%Session close to close
+14.6%Peak in 29 hr 47 min
$207.44MMarket Cap
1.0xRel. Volume
In the Feb 25 session, ELTX gained 10.35%, reflecting a significant positive market reaction.
Argus tracked a peak move of +14.6% during that session.
Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.
The stock surged +10.3% in the session following this news. A strong positive reaction aligns with t...
Analysis
The stock surged +10.3% in the session following this news. A strong positive reaction aligns with the stock’s recent pattern of constructive responses to news, such as prior clinical updates showing meaningful T cell activity. However, this conference appearance is mainly an investor-relations event, not a new data readout. With short interest around 19.72% and a relatively small float, squeezes and sharp reversals have been possible when sentiment or liquidity shifts.
Appointed CTO to lead CMC and operations ahead of ELI-002 7P DFS analysis.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news skewed to inducement grants and management updates, with modest price moves usually aligning with the news tone, except for one negative reaction to a CTO appointment.
Recent Company History
Over the last few months, Elicio has mainly reported inducement stock option grants and governance moves, alongside one notable Phase 2 AMPLIFY-7P update showing strong T cell responses. Inducement grants in Dec 2025–Feb 2026 saw generally small price gains or losses. A Nov 19, 2025 CTO appointment tied to preparations for the ELI-002 7P disease‑free survival analysis in 1H 2026 drew a negative reaction. Today’s conference participation fits within this cadence of corporate and investor-relations oriented news.
Key Terms
immunotherapies
1 terms
immunotherapiesmedical
"a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer"
Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.
BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, and Pete DeMuth, PhD, Chief Scientific Officer, will participate in the upcoming TD Cowen 46th Annual Health Care Conference, taking place March 2-4, 2026, in Boston, MA.
TD Cowen 46th Annual Health Care Conference Format: Company presentation Date: Wednesday, March 4, 2026 Time: 1:10 PM ET
The live webcast and replay of the presentation will be available HERE and on Elicio’s Events page for 90 days following the event.
If you are interested in arranging a 1×1 meeting with management at the conference, please contact your TD Cowen representative.
About Elicio Therapeutics
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical successes in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Elicio’s Amphiphile (“AMP”) technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 7P lead program is an off-the-shelf immunotherapy candidate targeting the most common KRAS mutations, which drives approximately 25% of all solid tumors. Elicio intends to expand ELI-002 7P clinical development not only for treatment in adjuvant pancreatic ductal adenocarcinoma (“PDAC”), but also in neoadjuvant and metastatic PDAC settings, and for other mKRAS-positive cancers. Off-the-shelf immunotherapy approaches have the potential benefits of low cost, rapid commercial scale manufacturing, and rapid availability of drug to patients especially in neo-adjuvant settings and for prophylaxis in high-risk patients, contrary to personalized immunotherapy approaches. ELI-002 is being studied in an ongoing, randomized clinical trial in patients with mKRAS-positive PDAC who completed standard therapy but remain at high risk of relapse. ELI-002 also has been studied in patients with mKRAS-positive colorectal cancer (“CRC”) in Phase 1 studies. The updated AMPLIFY-201 Phase 1 data for PDAC and CRC was presented at the ESMO Immuno-Oncology Congress 2024 and included a 16.3-month median recurrence-free survival and 28.9-month median overall survival for the full study population. Elicio’s pipeline includes additional off-the-shelf therapeutic cancer immunotherapy candidates, including ELI-007 and ELI-008, that target BRAF-driven cancers and p53 hotspot mutations, respectively. For more information, please visit www.elicio.com.
When will Elicio (ELTX) present at the TD Cowen Health Care Conference in 2026?
Elicio will present on March 4, 2026 at 1:10 PM ET. According to Elicio, the presentation is part of the TD Cowen conference running March 2-4, 2026 in Boston and will be available via live webcast and replay.
Who from Elicio (ELTX) will speak at the TD Cowen 46th Annual Health Care Conference?
CEO Robert Connelly and CSO Pete DeMuth will speak for Elicio. According to Elicio, both executives will participate in the company presentation and may be available for 1×1 meetings via TD Cowen.
How can investors watch Elicio's (ELTX) March 4, 2026 presentation online?
Investors can watch the live webcast and a 90-day replay on Elicio's Events page. According to Elicio, the webcast link will be posted for remote viewing and on-demand access after the event.
Can investors request a 1×1 meeting with Elicio (ELTX) management at the TD Cowen conference?
Yes, investors can request 1×1 meetings through their TD Cowen representative. According to Elicio, interested parties should contact TD Cowen to arrange meetings with management during March 2-4, 2026.
What topics will Elicio (ELTX) likely cover at the March 4, 2026 company presentation?
The presentation will cover recent clinical-stage immunotherapy developments and company progress. According to Elicio, executives will present updates relevant to investors and may discuss pipeline and scientific strategy.
Where will the replay of Elicio's (ELTX) TD Cowen presentation be available and for how long?
The replay will be available on Elicio's Events page for 90 days following the presentation. According to Elicio, the on-demand replay provides access for investors who miss the live webcast.
